Industrifonden Celebrates Successful Exit as Calliditas Therapeutics is Acquired by Asahi Kasei

Calliditas Therapeutics AB, a leading biopharmaceutical company focused on treating rare renal and hepatic diseases, has been acquired by Japanese multinational Asahi Kasei Corporation. The acquisition, valued at $1.1 billion, underscores Calliditas’s global impact and the importance of its innovative treatments.

With FDA and European Commission approvals in hand, Calliditas has established itself as the leading pharmaceutical company for treating IgA nephropathy. The acquisition is expected to accelerate the growth and global reach of Calliditas’s innovative treatment, further expanding their impact on patients suffering from chronic kidney inflammation and other serious conditions.

Industrifonden has been an early investor in Calliditas, recognizing the company’s potential to make a significant difference in the lives of patients with rare diseases. The partnership between Industrifonden and Calliditas has been instrumental in the company’s journey from a promising startup to a global leader in renal disease treatment.

Patrik Sobocki, Senior Investment Director at Industrifonden, commented on the acquisition:
“Calliditas is one of the most successful exits in Industrifonden’s history and the team at Industrifonden is proud to have contributed to the journey. The success reflects the hard work and dedication of the Calliditas team in developing life-changing treatments for patients worldwide. We are delighted to see Asahi Kasei recognize the value that Calliditas brings to the global healthcare landscape.”

Industrifonden remains committed to investing in groundbreaking companies that have the potential to transform industries and improve lives.